The AKAP12 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma cell line. This heterogeneous pool of gene-edited cells carries targeted disruptions of the AKAP12 locus, providing a loss-of-function model for functional studies. The polyclonal format avoids clonal selection artifacts and captures cellular heterogeneity, enabling robust investigation of AKAP12-dependent phenotypes in a cancer-relevant context.
The A-549 cell line is a classic in vitro model of non-small cell lung cancer (NSCLC), originally established from a 58-year-old Caucasian male with lung adenocarcinoma. These epithelial cells are extensively used to study NSCLC biology, including tumor suppressor mechanisms, cell migration, invasion, and drug sensitivity. Their lung origin and retained epithelial features make them particularly suitable for examining genes implicated in lung tumor progression and metastasis.
AKAP12 encodes a scaffold protein that anchors protein kinase A (PKA) and protein kinase C (PKC) to the plasma membrane and actin cytoskeleton, thereby coordinating cAMP-dependent and PKC-mediated signaling. It serves as a convergent node regulating focal adhesion dynamics, cytoskeletal remodeling, cell migration, and cell cycle progression. Upstream regulators include cAMP/PKA, PKC, Src kinase, EGF, and TGF-beta. AKAP12 directly interacts with PKA, PKC, Src, beta-adrenergic receptor, calmodulin, actin, myosin, and adducin, and modulates phosphorylation of downstream effectors such as vinculin, paxillin, beta-catenin, and cyclin D1. Loss of AKAP12 disrupts these complexes, leading to altered focal adhesion turnover, actin stress fiber reorganization, and enhanced motility??processes central to epithelial-mesenchymal transition and metastasis.
In A-549 lung adenocarcinoma cells, AKAP12 expression is often silenced, consistent with its proposed tumor-suppressive function. These polyclonal knockout cells, depleted of AKAP12, exhibit increased migratory and invasive potential driven by dysregulated beta-catenin signaling and focal adhesion instability. This model thus recapitulates key aspects of metastatic progression in NSCLC, providing a valuable tool to dissect AKAP12??s role in controlling cytoskeletal dynamics, cAMP-mediated growth suppression, and chemoresistance in a clinically relevant lung cancer background.
Researchers can employ this knockout model in a variety of assays: western blotting and RT-qPCR to verify gene disruption; migration and invasion assays to quantify motility changes; immunofluorescence to visualize focal adhesion proteins (e.g., vinculin, paxillin) and actin organization; phospho-PKA substrate western to monitor cAMP pathway activity; flow cytometry for cell cycle analysis; and co-immunoprecipitation to probe protein complex integrity. These approaches enable detailed mechanistic studies of AKAP12-dependent signaling in lung cancer. For ordering and technical support, contact Ascent Research.
